AGM/EGMApr 28, 2026, 04:32 PM
INCY 2026 AGM Set; 2025 Net Sales $4.35B, +20% YoY
AI Summary
Incyte Corporation announced its 2026 Annual Meeting of Shareholders will be held on June 8, 2026, to elect eight directors, approve executive compensation on an advisory basis, and ratify Ernst & Young LLP as the independent auditor. The company reported strong 2025 financial performance with net sales of $4.35 billion, a 20% year-over-year increase, driven by broad-based demand across its core business. Incyte also highlighted significant pipeline advancements, expecting 14 pivotal trials by the end of 2026.
Key Highlights
- Annual Meeting of Shareholders scheduled for Monday, June 8, 2026.
- 2025 net sales totaled $4.35 billion, representing 20% year-over-year growth.
- Core business sales (excluding Jakafi) reached $1.26 billion, a 53% increase from 2024.
- Jakafi sales contributed $3.09 billion in 2025, an 11% increase year-over-year.
- Opzelura net sales were $678 million in 2025, increasing 33% compared to prior year.
- Niktimvo achieved $152 million in net sales in its first year.
- Company expects 14 pivotal clinical trials underway by year-end 2026.
- Shareholders to vote on election of eight directors and auditor ratification.